Grade Post Therapy
Notes
**Note 1:** Leave post-therapy grade blank when * No neoadjuvant therapy * Clinical or pathological case only * There is only one grade available and it cannot be determined if it is clinical, pathological or post-therapy **Note 2:** Assign the highest grade from the resected primary tumor assessed after the completion of neoadjuvant therapy. **Note 3:** Codes 1-4 take priority over A-D, L and H. **Note 4:** CNS WHO classifications use a grading scheme that is a “malignancy scale” ranging across a wide variety of neoplasms rather than a strict histologic grading system that can be applied equally to all tumor types. * Code the WHO grading system for selected tumors of the CNS as noted in the AJCC 8th edition Table 72.2 where WHO grade is not documented in the record **Note 5:** Code 9 when * Surgical resection is done after neoadjuvant therapy and grade from the primary site is not documented * Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is availableNAACCR Item
NAACCR #3845Metadata
SSDI| Code | Description |
|---|---|
| 1 | WHO Grade I : Circumscribed tumors of low proliferative potential associated with the possibility of cure following resection |
| 2 | WHO Grade II: Infiltrative tumors with low proliferative potential with increased risk of recurrence |
| 3 | WHO Grade III: Tumors with histologic evidence of malignancy, including nuclear atypia and mitotic activity, associated with an aggressive clinical course |
| 4 | WHO Grade IV: Tumors that are cytologically malignant, mitotically active, and associated with rapid clinical progression and potential for dissemination |
| L | Stated as “low grade” NOS |
| H | Stated as “high grade” NOS |
| A | Well differentiated |
| B | Moderately differentiated |
| C | Poorly differentiated |
| D | Undifferentiated, anaplastic |
| 9 | Grade cannot be assessed (GX); Unknown |
| <BLANK> | See Note 1 |